

## Date: April 25, 2022

То,	То,
The Manager, Listing Department,	The Department of Corporate Service,
National Stock Exchange of India Limited	BSE Limited
(NSE),	1 <sup>st</sup> Floor, New Trading Ring,
Exchange Plaza, C-1, Block-G, Bandra - Kurla	Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal
Complex, Bandra (E), Mumbai-400 051.	Street, Mumbai-400 001.
Scrip Code – LINCOLN	Scrip Code – 531633

Dear Ma'am / Sir,

## SUB: **REPORTING OF INITIAL DISCLOSURE TO BE MADE BY ENTITIES IDENTIFIED AS LARGE** CORPORATES.

Pursuant to the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018 ("Circular"), we hereby confirm that the Company i.e. Lincoln Pharmaceuticals Ltd is not falling under the category of Large Corporate Entity as per the framework / applicability criteria mentioned in clause 2.2 of the said circular as on March 31, 2022.

Accordingly the initial disclosure in "Annexure A" to the said circular is not applicable to us.

Kindly take the above on record.

Thanking you.

Yours faithfully For Lincoln Pharmaceuticals Ltd MA AHMEDABA Niren A. Desai

**Company Secretary &** 

## **Compliance Officer**

Regd. Office : "Lincoln House", B/h. Satyam Complex, Science City Road, Sola, Ahmedabad-380 060, Gujarat, India. Phone: +91-79-4107 8000 | CIN L24230GJ1995PLC024288 E-mail : info@lincolnpharma.com | Website : www.lincolnpharma.com



Factory : Trimul Estate, Khatraj-382721, Tal.-Kalol, Dist.- Gandhinagar, Gujarat, India. Phone:+91-79-4913 5000 | E-mail:khatraj@lincolnpharma.com